Medscape

FDA Approves Once-Monthly Paliperidone Palmitate Injection for Treating Schizophrenia

August 5, 2009 — The US Food and Drug Administration (FDA) has approved a long-acting, once-monthly formulation of paliperidone palmitate injection (Invega Sustenna, Janssen, a division of ...
Monthly Prescribing Reference

Invega Hafyera Approved for Twice-Yearly Treatment of Schizophrenia

The Food and Drug Administration has approved Invega Hafyera ™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting ...
Healthline

Dosage Details for Invega Trinza

If you have schizophrenia, your doctor might suggest Invega Trinza as a treatment option for you. Invega Trinza is a prescription medication that treats schizophrenia in adults. It can be used in ...
FiercePharma

New Data on INVEGA(R) SUSTENNA(R) and RISPERDAL(R) CONSTA(R) for Schizophrenia to be Presented at Major Psychiatry Meeting

TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...
FiercePharma

Study Published in The Journal of Clinical Psychiatry Shows INVEGA SUSTENNA® Effective Six Months Longer Than Common Oral Antipsychotics in Treatment of Schizophrenia

Trial is the first to study schizophrenia treatment within the context of many real-world issues faced by patients with schizophrenia TITUSVILLE, N.J., April 15, 2015 /PRNewswire/ -- A study published ...
News Medical

Janssen announces CHMP positive opinion for use of paliperidone palmitate 3-monthly injection for schizophrenia treatment

If approved, paliperidone palmitate 3-monthly injection will be the first once-every-three-months treatment for schizophrenia in the UK Janssen UK announced today that the Committee for Medicinal ...
News Medical

Invega Hafyera

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. INVEGA HAFYERA contains the active ingredient paliperidone palmitate.
Medscape

FDA Approves First Twice-Yearly Antipsychotic for Schizophrenia

The US Food and Drug Administration (FDA) has approved a 6-month injection form of the long-acting atypical antipsychotic paliperidone palmitate (Invega Hafyera, Janssen Pharmaceuticals) for the ...
FierceBiotech

J&J trumpets early success for 3-month Invega Sustenna PhIII schizophrenia trial

Johnson & Johnson wrapped a Phase III study of a 3-month formulation of Invega Sustenna early after an independent monitoring group called it on positive efficacy ...
The Motley Fool

Could This Game-Changing FDA Approval Mean Profit for Johnson & Johnson Shareholders?

Invega Hafyera is the third drug in Johnson & Johnson's Invega franchise to be approved, joining the monthly Invega Sustenna and quarterly Invega Trinza. Based on Invega Hafyera's similar efficacy to ...
Healthline

Invega interactions: Alcohol, Medications, and Others

Invega (paliperidone) is a prescription drug that’s used to treat schizophrenia. This drug can interact with alcohol and some other medications. For example, Invega can interact with azithromycin and ...